# Sana Biotechnology **Source:** https://geo.sig.ai/brands/sana-biotechnology **Vertical:** Biotechnology **Subcategory:** Gene Therapy **Tier:** Emerging **Website:** sana.com **Last Updated:** 2026-04-14 ## Summary Sana Biotechnology develops engineered cell and gene therapies with fusogen delivery technology to treat serious diseases through in vivo and ex vivo approaches. ## Company Overview Sana Biotechnology is a publicly traded gene therapy company founded in 2018 by veterans of Juno Therapeutics and other leading cell therapy companies. The company is building technologies to repair or replace any gene in any cell, with a particular focus on its proprietary fusogen-based delivery platform that enables engineered cells to fuse with and deliver genetic material to specific target cells in the body. This approach could enable off-the-shelf cell therapies and in vivo gene editing without the need to harvest and engineer patient cells individually. Sana has programs targeting blood cancers, autoimmune diseases, and type 1 diabetes, exploring both in vivo gene delivery and ex vivo engineered cell therapies. The company went public through an IPO in 2021, raising substantial capital to advance its novel platform. Sana has formed research collaborations with academic institutions and pharmaceutical companies to advance specific programs. The company represents the cutting edge of cell and gene therapy with proprietary delivery technologies that could unlock new therapeutic approaches beyond what current viral vector and CRISPR systems enable. ## Frequently Asked Questions ### What is Sana Biotechnology? Sana Biotechnology is developing engineered cell and gene therapies using proprietary fusogen delivery technology to treat blood cancers, autoimmune diseases, and metabolic disorders through both in vivo and ex vivo approaches. ### What is Sana's fusogen technology? Sana's fusogen technology uses engineered proteins to enable cells to fuse and deliver genetic cargo to specific target cells in the body, potentially enabling off-the-shelf cell therapies and in vivo gene editing with greater precision and accessibility. ### Is Sana Biotechnology publicly traded? Yes, Sana Biotechnology went public on Nasdaq in 2021 and is a clinical-stage company advancing its novel gene and cell therapy platform with programs targeting hematological malignancies, autoimmune disease, and type 1 diabetes. ### What diseases is Sana Biotechnology targeting? Sana's clinical and preclinical programs target hematological malignancies (blood cancers), autoimmune diseases including type 1 diabetes, and metabolic conditions. The company's gene and cell therapy platform aims to address diseases where modifying or replacing specific genes in affected cells could provide durable therapeutic benefit. ### What is the difference between Sana's in vivo and ex vivo approaches? Ex vivo approaches involve removing cells from a patient, engineering them in a lab, and infusing them back — the approach used in approved CAR-T cell therapies. Sana's in vivo approach uses fusogen delivery to engineer cells directly inside the body without cell extraction, potentially enabling simpler, off-the-shelf treatments for a broader range of conditions. ### Who are Sana Biotechnology's founders? Sana was founded in 2018 by veterans of Juno Therapeutics and other leading cell and gene therapy companies, including Hans Bishop (former Juno CEO) and a team with deep experience in the CAR-T cell therapy field. The company raised approximately $700 million in a 2021 IPO on NASDAQ (SANA). ### What is the current stage of Sana's clinical programs? Sana has programs in Phase 1 clinical trials for its engineered cell therapy candidates targeting hematologic malignancies. The company is an early-stage clinical company, meaning it has not yet reported efficacy data from controlled trials — it is still establishing safety and early activity signals in humans. ### What makes Sana's off-the-shelf cell therapy approach significant? Current approved CAR-T therapies are autologous (made from each patient's own cells), requiring weeks of manufacturing per patient at high cost. Sana's fusogen technology could enable allogeneic (off-the-shelf) cell therapies made from healthy donor cells that can be given to any patient immediately — potentially making cell therapy faster, cheaper, and more widely accessible. ### Who founded Sana Biotechnology? Sana was founded in 2018 by Steve Harr, former CFO of Juno Therapeutics, along with a team of cell and gene therapy veterans, and has assembled scientific advisors including recognized leaders in gene delivery and cell engineering. ### What autoimmune programs is Sana pursuing? Sana is developing hypoimmune cell therapies for type 1 diabetes and autoimmune diseases, using its fusogen technology to deliver gene-corrected cells that evade immune rejection without requiring immunosuppression. ### What is hypoimmune engineering and why does it matter? Hypoimmune cells are engineered to avoid detection and destruction by the recipient's immune system, enabling allogeneic (off-the-shelf) cell therapies that do not require donor-matched cells or immunosuppressive drugs, potentially making cell therapy far more accessible. ### How much has Sana raised? Sana raised approximately $576 million in its 2021 Nasdaq IPO — one of the largest biotech IPOs of that year — providing substantial capital for its multi-program cell and gene therapy pipeline. ### What is Sana's near-term clinical focus? Sana's near-term programs include SC291, an allogeneic CAR-T targeting CD19 for B cell malignancies, and in vivo gene delivery programs for hematological diseases using its fusogen LNP delivery technology. ## Tags startup, healthtech, technology, public, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*